AC Immune SA
AC Immune SA (ACIU) Historical Volatility
ACIU's 30 day historical volatility is 70.54%, in the 69th percentile of readings over the past year. This is an average percentile, meaning AC Immune SA shares have moved roughly in line with their typical range. ACIU's 30 day implied volatility sits at 269.85%, with an IV Rank of 70.24%, leaving IV 199.31 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking ACIU historical volatility helps you see how much AC Immune SA's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ACIU's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ACIU 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ACIU's 30 day historical volatility, or ACIU HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ACIU's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD).
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →